Orbis Biosciences, Inc.

Lenexa, KS 66214

SBIR Award Summary

Total Number of Awards 15
Total Value of Awards $6.31MM
First Award Date 06/15/10
Most Recent Award Date 07/07/17

Key Personnel

Last Name Name Awards Contact
Berkland Cory Berkland 5
Beyerinck Ronald Arthur Beyerinck 2
Flynn Maria Flynn 4 Message
Newbold David N. Newbold 2
Dormer Nathan H Dormer 11 Message
Dumbauld David Dumbauld 2
Singh Milind Singh 4 Message

15 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 07/07/17 - 06/30/18

PROJECT SUMMARY Current approaches to treat sensorineural hearing loss (SNHL) in newborns suffering from congenital cytomegalovirus (CMV) infection rely on off-label, systemic antiviral therapy requiring high dose, long duration treatment with demonstrated hematologic toxicity, carcinogenicity, and teratogenicity. Furthermore, it is unknown whe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/01/16 - 08/31/17

? DESCRIPTION (provided by applicant): New treatment options are needed for inner ear disorders including Meniere's disease, sensorineural hearing loss, autoimmune inner ear disease, and tinnitus. In the absence of FDA-approved drugs, physicians use improvised treatments, including the administration of off-label steroids, which lack safety a...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water-soluble compounds. Although these poorly water-soluble drugs are projected to have high clinical efficacy, they are often rejected in the early stages of re...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water-soluble compounds. Although these poorly water-soluble drugs are projected to have high clinical efficacy, they are often rejected in the early stages of re...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): New treatment options are needed for inner ear disorders including Meniere's disease, sensorineural hearing loss, autoimmune inner ear disease, and tinnitus. In the absence of FDA-approved drugs, physicians use improvised treatments, including the administration of off-label steroids, which lack safety and ef...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 08/01/15 - 07/31/16

DESCRIPTION (provided by applicant): New dosage forms are needed to address the shortcomings of current practice with regard to administration of medications to pediatric populations. Specifically, in the absence of pediatric-specific products - formulations that are both palatable (to ensure compliance) and titratable (to meet the weight/surfac...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 09/30/14 - 07/31/15

DESCRIPTION (provided by applicant): New dosage forms are needed to address the shortcomings of current practice with regard to administration of medications to pediatric populations. Specifically, in the absence of pediatric-specific products - formulations that are both palatable (to ensure compliance) and titratable (to meet the weight/surfac...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 09/01/14 - 08/31/15

DESCRIPTION (provided by applicant): A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water-soluble compounds. Although these poorly water-soluble drugs are projected to have high clinical efficacy, they are often rejected in the early stages of re...

Phase 1 SBIR

Agency: Department of Agriculture
Topic: 8.3-2014
Budget: 01/01/14 - 12/31/14

Vaccination is a particularly powerful weapon in the fight against wide-spread livestock disease. Commercially available vaccines, however, are often difficult and costly for livestock producers to use properly, leaving individual animals - and by extension the global food supply - at risk. More specifically, many vaccines on the market today re...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 09/20/13 - 08/31/14

DESCRIPTION (provided by applicant): A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water-soluble compounds. Although these poorly water-soluble drugs are projected to have high clinical efficacy, they are often rejected in the early stages of re...

Load More